Comparison of the Efficacy of Generation 1 and 2 Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients with EGFR Positive Mutations. Indian Journal of Forensic Medicine & Toxicology, [S. l.], v. 15, n. 3, p. 4316–4324, 2021. DOI: 10.37506/ijfmt.v15i3.15970. Disponível em: https://medicopublication.com/index.php/ijfmt/article/view/15970. Acesso em: 7 may. 2026.